NOVA

University of Newcastle Research Online

nova.newcastle.edu.au

Scott, H. A.; Gibson, P. G.; Garg, M. L.; Pretto, J. J.; Morgan, P. J.; Callister, R.; Wood, L. G "Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial", Clinical and Experimental Allergy Vol. 43, Issue 1, p. 36-49 (2013)

Available from: <http://dx.doi.org/10.1111/cea.12004>

This is the peer reviewed version of the following article: Scott, H. A.; Gibson, P. G.; Garg, M. L.; Pretto, J. J.; Morgan, P. J.; Callister, R.; Wood, L. G "Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial", Clinical and Experimental Allergy Vol. 43, Issue 1, p. 36-49 (2013) which has been published in final form at <http://dx.doi.org/10.1111/cea.12004>. This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#)

Accessed from: <http://hdl.handle.net/1959.13/1067304>

Dietary Restriction and Exercise Improve Airway Inflammation and Clinical Outcomes in Overweight and Obese Asthma: A Randomised Trial

Condensed Title: Weight Loss in Asthma: A Randomised Trial

^{1,2}Hayley A Scott, PhD; ^{1,2}Peter G Gibson, MBBS; ³Manohar L Garg, PhD; ^{1,2}Jeffrey J Pretto, PhD; ⁴Philip J Morgan, PhD; ³Robin Callister, PhD; ^{1,3}Lisa G Wood, PhD.

¹Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW Australia 2305.

²School of Medicine and Public Health, The University of Newcastle, NSW Australia 2308.

³School of Biomedical Sciences and Pharmacy, The University of Newcastle, NSW Australia 2308

⁴Faculty of Education and Arts, Priority Research Centre in Physical Activity and Nutrition, The University of Newcastle, NSW Australia, 2308.

Corresponding Author:

Dr Lisa Wood, Lisa.Wood@newcastle.edu.au

Phone: +61249855677

Fax: +61249855850

Department of Respiratory and Sleep Medicine, HMRI, Level 3, John Hunter Hospital
Lookout Rd, New Lambton Heights NSW 2305, Australia

Key Words: adipose tissue, asthma, body composition, low-energy diet, eosinophil, exercise, neutrophil, obesity, weight loss

ABSTRACT:

Background:

Obesity and asthma are associated conditions, however the mechanisms linking the two remain unclear. Few studies have examined the effects of weight loss on inflammation and clinical outcomes in obese-asthma.

Objective:

To compare the effects of weight loss achieved by dietary restriction, exercise, or combined dietary restriction and exercise, on airway inflammation and clinical outcomes in overweight and obese adults with asthma.

Methods:

Participants (n= 46; 54.3% female, BMI (mean $\pm$ SD) 33.7 $\pm$ 3.5kg/m²) were randomised to complete a 10-week dietary, exercise or combined dietary and exercise intervention. Dual-energy x-ray absorptiometry was performed, the Juniper Asthma Control Questionnaire and Juniper Asthma Quality of Life Questionnaire completed, and inflammatory markers, dietary intake and physical activity measured. The trial was registered with the Australian Clinical Trials Registry: ACTRN12611000235909.

Results:

Retention was 82.6%. Mean $\pm$ SD weight loss was 8.5 $\pm$ 4.2%, 1.8 $\pm$ 2.6% and 8.3 $\pm$ 4.9% after the dietary, exercise and combined interventions, respectively. Asthma control improved after the dietary (mean $\pm$ SD; -0.6 $\pm$ 0.5, p =<0.001) and combined interventions (-0.5 $\pm$ 0.7, p =0.040), while quality of life improved after the dietary (median [IQR]; 0.9 [0.4, 1.3], p =0.002), exercise (0.49 [0.03, 0.78], p =0.037) and

combined (0.5 [0.1, 1.0], $p=0.007$) interventions. A 5-10% weight loss resulted in clinically important improvements to asthma control in 58%, and quality of life in 83%, of subjects. Gynoid adipose tissue reduction was associated with reduced neutrophilic airway inflammation in females (β -coefficient [95%CI]; 1.75 [0.02, 3.48], $p=0.047$), while a reduction in dietary saturated fat was associated with reduced neutrophilic airway inflammation in males ($r=0.775$, $p=0.041$). The exercise intervention resulted in a significant reduction to sputum eosinophils [median [IQR]; -1.3 (-2.0, -1.0)%, $p=0.028$].

Conclusions and Clinical Relevance:

This study suggests a weight loss goal of 5-10% be recommended to assist in the clinical management of overweight and obese adults with asthma. The obese-asthma phenotype may involve both innate and allergic inflammatory pathways.

INTRODUCTION

Obesity is a risk factor for asthma, with asthma incidence being almost doubled in obese compared with healthy weight individuals [1]. Obese asthmatics experience more severe asthma symptoms, reduced lung function, have a poorer quality of life [2-6], and a reduced response to inhaled corticosteroid medication [4, 7, 8], the mainstay of asthma pharmacotherapy. This highlights the need for alternative treatment strategies to effectively manage asthma in this population.

Weight loss induced by either caloric restriction or bariatric surgery appears to improve asthma symptoms, lung function and quality of life [9-12]; however, most studies have not measured asthma objectively or as the primary outcome [10, 13-17]. The effect of weight loss on airway inflammation has been examined by Dixon et al [18], who reported no change after surgically-induced weight loss. To our knowledge, the effect of exercise has yet to be investigated as a weight loss strategy in an asthmatic population. This is important because exercise is associated with reduced asthma exacerbations [19], asthma symptoms [20] and bronchial hyperresponsiveness in an asthmatic population. Furthermore, asthmatics are less likely to exercise than non-asthmatics [20], while obese individuals are less likely to exercise compared with those of a healthy weight [21]. These studies suggest that obese asthmatics generally have a low exercise level, which may have a role in the aetiology of the obese-asthma phenotype.

The mechanisms driving the obese-asthma phenotype are not well understood, however it appears to involve a predominantly female population with a high symptom expression despite an absence of airway eosinophils [22]. We have

proposed previously that this non-eosinophilic obese-asthma phenotype may in fact represent neutrophilic asthma, as we observed a positive association between body mass index (BMI) and sputum neutrophils in asthmatic females, but not males [23]. This observation is important because neutrophilic airway inflammation is associated with the most severe forms of asthma [24] and is resistant to inhaled corticosteroid medication [25]. Others have since demonstrated an association between obesity and neutrophil concentrations in both the airways [26] and circulation [5, 26, 27] of adults with asthma.

It is uncertain whether weight loss reduces neutrophilic airway inflammation. We therefore sought to examine the effect of weight loss on the inflammatory and clinical outcomes of overweight and obese adults with asthma. Whether physical inactivity has a role in the aetiology of the obese-asthma phenotype is also uncertain. Therefore, we also sought to examine the effects of increased exercise on clinical asthma outcomes and airway inflammation. We hypothesised that both weight loss induced by caloric restriction, and increased exercise, would improve clinical asthma outcomes in overweight and obese asthma. We also hypothesised that weight loss would be associated with a reduction in airway neutrophils in females and significantly improve clinical asthma outcomes. The aim of this study was to compare the effects of weight loss and increased exercise achieved by a dietary intervention, exercise intervention and combined dietary and exercise intervention, on airway inflammation and the clinical asthma outcomes of overweight and obese males and females with asthma.

METHODS

Study Design

Participants were randomised between June 2009 and December 2010 to complete a 10-week dietary intervention, exercise intervention, or combined dietary and exercise intervention (Figure 1). Participants were overweight and obese (BMI 28-40kg/m²) non-smoking adults with asthma. Asthma was defined by doctor's diagnosis and documented history of airway hyperresponsiveness (AHR), however there were no entry criteria in relation to symptom severity or lung function. Exclusion criteria included: weight change >5% in the preceding three months; pregnancy or breastfeeding; cardiac arrhythmia or angina; renal or hepatic failure; use of insulin or oral hypoglycaemic medication; gallstones, pancreatitis, cancer; or an orthopaedic problem that would impede physical activity. Participants were deemed medically fit for weight loss through a screening examination and written approval from their primary healthcare provider. All clinical measures were performed pre- and post-intervention at the John Hunter Hospital, NSW, Australia. Recruitment was conducted in blocks of up to five participants, who were blind to group allocation until completion of their baseline assessment. Computer-generated blocks of random numbers were generated by the statistician, which randomised participants within each block. These randomisation codes were held by the statistician and concealed to study personnel. Once each block was scheduled and confirmed by study personnel, the study coordinator contacted the statistician by email. At this point the statistician revealed the next block allocation. Once this was revealed, study personnel were not permitted to enrol additional participants to that particular block. Due to the nature of the interventions, it was not possible to blind the researchers or participants during the study intervention. Hence, to reduce risk of bias, objective outcomes measures were

used, including lung function, anthropometry and inflammatory markers. This research was approved by the Hunter New England Human Research Ethics Committee and all subjects provided written informed consent. The trial was registered with the Australian Clinical Trials Registry (<http://www.actr.org.au>), Registration Number: ACTRN12611000235909.

Intervention Descriptions

Dietary Intervention

Participants were prescribed an intake of 3700-4900 kilojoules (kJ)/day (885-1170kcal/day), including two meal replacements per day provided free of charge (Optifast® VLCD™, Nestle Nutrition, Australia; and/or KicStart™ VLCD, Prima Health Solutions, Frenchs Forest, Australia). Participants were also instructed to consume one main meal and snacks daily, and complete weekly counselling with a dietitian: seven one-hour clinic visits and four ten-minute phone consultations. These sessions focused on nutrition education, behaviour modification and motivational strategies. Participants maintained a daily food diary for the duration of the intervention, which included details on hunger perception, water intake and food habits, in addition to actual food eaten.

Exercise Intervention

Participants received a 12-week gymnasium membership and a group personal training session for one hour each week. All sessions were completed at the same gymnasium to ensure comparable exercise programs were undertaken. Each program was designed by an exercise physiologist, and included both aerobic activities and resistance training. Participants attended the gymnasium at least three times each

week and wore a pedometer daily for the duration of the intervention, with the goal of increasing their daily steps by 10% each week to a target of 10,000 steps per day. Participants received educational materials regarding national physical activity recommendations, set goals with the study dietitian and signed an informal contract prior to commencing their first gymnasium session. Participants also completed a daily physical activity diary throughout the intervention, which included space to list activities completed each day, daily pedometer step goals and a section for comments and resolutions.

Combined (Dietary + Exercise) Intervention

Participants completed both the dietary and exercise interventions concurrently.

Anthropometric Measurements

Height, weight (Nuweigh LOG 842, NWS, Newcastle Australia) and waist circumference [28] were measured by trained research assistants. A total body scan was performed using dual-energy x-ray absorptiometry (DXA) (Lunar Prodigy Series, GE Medical Systems, Madison USA) after subjects removed unfixed metal objects. Percentage fat change was calculated as $[(\text{post-intervention fat mass (g)} - \text{pre-intervention fat mass (g)}) / \text{pre-intervention fat mass (g)}] \times 100$. DXA regions were defined as described previously [29]. Quality assurance and quality control measures were performed in accordance with the manufacturer's instructions.

Dietary Intake and Physical Activity Level

Four-day semi-quantitative food diaries were completed prior to randomisation and during the final week of the intervention. Data was entered by a dietitian and analysed

using nutrient analysis software (FoodWorks Professional Edition Version 6.0, Xyris Software Pty Ltd, Australia). The short form of the International Physical Activity Questionnaire (IPAQ) was used to quantify physical activity levels and daily sitting time [30], and a categorical variable was generated according to IPAQ guidelines [31]. Participants wore a pedometer for seven days and recorded their steps in a diary, prior to randomisation and during the final week of the intervention (Yamax Digi-Walker SW 700, Tokyo Japan).

Asthma Symptoms, Lung Function Testing, Sputum Induction and Processing

Asthma control was quantified using the Juniper Asthma Control Questionnaire (ACQ) [32], while asthma-related quality of life was assessed by the Juniper Asthma Quality of Life Questionnaire (AQLQ) [33]. Clinically significant improvements in ACQ and AQLQ scores were defined by a reduction in the ACQ score of ≥ 0.5 [34] and an increase in the AQLQ score of ≥ 0.5 [35], respectively. Lung function was measured in accordance with American Thoracic Society and European Respiratory Society guidelines [36, 37]. Dynamic lung function (forced expiratory volume in 1 second, FEV₁ and forced vital capacity, FVC) was measured using a Koko Spirometer (POS Instrumentation, Inc, Louisville USA) and static lung function (total lung capacity, TLC; functional residual capacity, FRC; expiratory reserve volume, ERV; and residual volume, RV) using a computerised body-plethysmograph system (Vmax Encore, Sensormedics Corp., Yorba Linda, Ca, USA). Sputum induction coupled with bronchial provocation using 4.5% hypertonic saline was performed over a standardised 15.5 minutes nebuliser time [38]. A decrease in FEV₁ $\geq 15\%$ from baseline was indicative of airway hyperresponsiveness. Provocation dose (PD₁₅) was calculated and β_2 -agonist (salbutamol 200 μ g) administered [38]. Lower respiratory

sputum portions were selected and dispersed using dithiothreitol. Total cell counts and cell viability were determined by haemocytometer. Differential cell counts were determined from cytopins, which were prepared, stained and counted from 400 non-squamous cells.

Inflammatory Markers

Venous blood was collected after a 12-hour overnight fast. High sensitivity C-reactive protein (CRP) was measured in heparinised plasma using the CRP Flex® reagent cartridge (Siemens Healthcare Diagnostics Inc., Newark USA) and automatically analysed by the Dimension Vista® System (Siemens Healthcare Diagnostics Inc., Newark USA). A commercial ELISA was used to measure plasma IL-6 (R&D Systems, Minneapolis MN USA), and commercial assays used to measure serum leptin and adiponectin (Bio-Rad, Hercules CA USA).

Statistical Analysis

Data were analysed using Intercooled Stata version 11.1 (Stata Corporation, College Station TX USA) with results reported as median (IQR), mean $\pm$ SD or the percentage of subjects with the specified variable. Per-protocol analysis of covariance (ANCOVA) was used to compare pre- and post-intervention data, rather than intention to treat analysis. Change was also examined using Wilcoxon signed rank test or a paired *t*-test, divided by intervention group. The associations between changes in airway inflammation and exercise were determined by partial correlations, adjusted for the effects of age and inhaled corticosteroid (ICS) use. Sex-specific associations between airway inflammation, body composition, dietary fat intake and systemic inflammation were determined by partial correlations, adjusted for age and ICS use.

Dietary fat intake was also adjusted for total kilojoule intake. Change in gynoid fat (%) was examined by multiple linear regression, as a predictor of sputum neutrophils in males and females with asthma. These models were adjusted for age and ICS use. Change in neutrophilic airway inflammation was analysed by two-factor ANOVA after adjustment for age and ICS use to determine the interactions between sex, and body composition and dietary fat. The robust variance estimator was applied to nonparametric variables to account for the outcome being skewed. *P*-values ≤ 0.05 were considered statistically significant.

RESULTS

Participant Demographics

Forty-six participants were randomised and 38 completed the trial (82.6% retention) (Figure 1). All groups had a similar baseline age, sex, body composition, asthma status and sputum inflammatory profile (Table 1). The mean ACQ score was 1.2 ± 0.6 , indicative of partially controlled asthma [39]. Almost 25% of participants reported hypertension; 25% reported back, knee or shoulder pain; 25% reported sinus or hayfever; 25% depression or anxiety; and 8% reported having previously had a cholecystectomy (Table 1).

Anthropometric Characteristics

Subjects had a mean weight reduction of $8.5 \pm 4.2\%$ after the dietary intervention, $1.8 \pm 2.6\%$ after the exercise intervention and $8.3 \pm 4.9\%$ after the combined intervention (Figure 2a). Exercise was less effective at reducing body weight, waist circumference, total body fat and fat within the thoracic, gynoid and leg regions relative to the other interventions (Table 2). All interventions resulted in a significant reduction in waist circumference (Figure 2b) and android fat mass (Table 2). Fat mass was decreased in all regions after the dietary and combined interventions (Figure 2c, Table 2), while lean mass was conserved as a result of the exercise and combined interventions (Figure 2d).

Nutrient Intake

The dietary and combined interventions resulted in a significantly lower kilojoule, dietary fat and carbohydrate intake, relative to the exercise intervention (Table 2). Macronutrient intake was not altered after the exercise intervention (Table 2).

Physical Activity

At baseline, 29% of participants had a low physical activity level and 24% a moderate physical activity level, determined by IPAQ. After the exercise and combined intervention, 80% ($p=0.025$ vs baseline) and 92% ($p=0.063$ vs baseline) of participants, respectively, were classified as having a high physical activity level. Physical activity was also examined as a continuous variable. The exercise group had a significant increase in physical activity ($p=0.022$) and significant reduction in physical inactivity (sitting time) ($p=0.031$) (Table 2). Pedometer step counts did not significantly change after the exercise or combined interventions, however step counts were already close to the 10,000 steps/day target prior to intervention commencement (Table 2).

Clinical Asthma Status Change with Weight Loss

Effect of Diet and/or Exercise on Clinical Asthma Status

TLC was significantly improved after the exercise and combined interventions relative to the dietary intervention (Table 3), while ERV was improved after the dietary intervention (Table 3). All three interventions improved AQLQ score (Figure 3a), with clinical improvements in 73% of subjects after the dietary intervention and 50% of subjects after both the exercise and combined interventions ($p=0.365$ for between-group comparison) (Figure 3b). ACQ was improved after the dietary and combined interventions (Figure 3c), with clinically significant improvements in 53% and 42% of subjects respectively ($p=0.250$ for between-group comparison) (Figure 3d). Males and females experienced a similar degree of improvement to ACQ and AQLQ ($p>0.05$). The proportion of subjects with airway hyperresponsiveness

[measured as PD₁₅ (mL)] decreased significantly from pre- to post-intervention in the combined group (100% vs 66.7% respectively, $p=0.027$), with a non-significant trend for the dietary (66.7% vs 40.0% respectively, $p=0.143$) and exercise groups (60.0% vs 30.0% respectively, $p=0.178$).

Impact of Degree of Weight Loss on Clinical Asthma Status

A modest (5-10%) weight loss resulted in significant improvements to FVC, AQLQ and ACQ (Table 4), with clinically important improvements to AQLQ (Figure 3e) and ACQ (Figure 3f) in 83% and 58% of participants, respectively. A greater weight loss (>10%) did not confer additional benefit to AQLQ or ACQ, despite a greater improvement to lung function (Table 4). While weight loss <5% significantly improved ACQ and AQLQ (Table 4), the proportion of subjects who had a clinically significant improvement to their ACQ and AQLQ was substantially lower compared with subjects who lost between 5-10% body weight (Figure 3e and 3f). Furthermore, there was no significant change to lung function with a weight loss <5% (Table 4). Seven subjects who lost 5-10% body weight had poorly controlled asthma at baseline; five became partially controlled (71%) and one well controlled (14%) after weight loss. Four subjects who lost >10% body weight had poorly controlled asthma at baseline; 75% became well controlled and 25% partially controlled. Only one subject losing <5% body weight was poorly controlled at baseline, and remained so after the intervention.

Inflammatory Changes After Weight Loss

Serum leptin was significantly reduced after the dietary and combined interventions, while IL-6 was reduced after the combined intervention (Table 3). Sputum samples

were successfully obtained both pre- and post-intervention from 76% of participants. %Sputum eosinophils were significantly reduced in subjects who completed the exercise intervention ($p=0.028$) (Table 3) and, consequently, the effect of exercise was examined in the overall cohort. An increase in moderate-intensity exercise correlated with a reduction in sputum %eosinophils, while there was a trend between increased walking and reduced sputum %eosinophils ($p=0.071$) (Table 5).

There was a positive correlation between change in sputum %neutrophils and %weight change in females (Table 6). This was confirmed by DXA, which demonstrated a positive correlation between change in sputum %neutrophils and change in total %fat and %fat within the gynoid, leg and arm regions (Table 6). Linear regression was performed, illustrating an association between change in sputum %neutrophils and change in %gynoid body fat in females (β -coefficient [95%CI] = 1.75 [0.02, 3.48], $p=0.047$). In this model, for every 1% fat loss from the gynoid region, there was a corresponding reduction in sputum %neutrophils of 1.7%. This relationship was not observed in males ($p=0.831$); however, there was an association between reductions in saturated fat intake and absolute counts of sputum neutrophils ($r=0.775$, $p=0.041$) (data not shown) and a trend toward reduced sputum %neutrophils ($r=0.472$, $p=0.286$) (Table 6). The results of two-factor ANOVA demonstrate an interaction between sex and weight loss (%weight loss, %android fat loss, %arm fat loss), whereby being female resulted in a significantly greater reduction to sputum %neutrophils compared with being male ($p<0.05$ for each, data not shown). There was not an interaction between sex and dietary fat intake in relation to neutrophilic airway inflammation (data not shown).

DISCUSSION

This study demonstrates that modest weight loss (5-10% body weight) is sufficient to improve lung function, asthma control and quality of life in overweight and obese adults with asthma. Dietary restriction, with or without exercise, resulted in a greater weight loss than exercise alone, and provided greater benefit in terms of asthma control. There was a correlation between a reduction in neutrophilic inflammation, and weight loss in females and saturated fat reduction in males, while exercise resulted in a significant reduction to sputum eosinophils. Furthermore, while dietary restriction achieved a greater weight loss compared with exercise, exercise improved lung function (ERV) to a greater degree than dietary restriction.

This is the first study to demonstrate that dietary restriction using meal replacements and exercise are efficacious strategies for improving body composition and clinical outcomes of overweight and obese adults with asthma. A modest weight loss of 5-10% is recommended for overweight and obese individuals, as it is a realistic weight loss goal [40] and favourably modifies cholesterol, triglycerides, insulin resistance and blood pressure [41, 42]. We have demonstrated that this degree of weight loss also alleviates asthma symptoms. Therefore, a weight loss goal of 5-10% may aid in the clinical management of overweight and obese individuals with asthma.

This study has advanced our understanding of obese-asthma in females, as fat reduction within the gynoid, leg and arm regions correlated with a reduction in sputum neutrophils. This is an important finding and supports our previous observation, where BMI and neutrophilic airway inflammation were positively associated in females [23]. The current study extends on this, by demonstrating

neutrophilic airway inflammation can be reduced with adipose tissue reduction. Neutrophils are more highly activated in the circulation [43] and adipose tissue vasculature [44] of obese individuals, and our work suggests that this inflammation extends to the airways of females with asthma. The mechanism by which this occurs is uncertain, however it is possible that the relationship is mediated by leptin. Leptin is highly correlated with adiposity, particularly with subcutaneous adiposity, which is abundant within the gynoid region of females [45]. Leptin enhances the Th1 response and increases the activation of neutrophils via TNF- α [46, 47]. Our study demonstrates a non-significant correlation between changes in circulating leptin and airway neutrophils. Investigation in a larger population powered to perform this analysis is warranted.

Reduced saturated fat intake was associated with a reduction in neutrophilic airway inflammation in males. Again, this supports our previous work, where plasma saturated fatty acids and neutrophilic airway inflammation were positively associated in males [23]. Males have a significantly higher rate of fatty acid uptake and lipolysis within the visceral abdominal region [48, 49]. These fatty acids are primarily transported to the liver where they encounter Kupffer cells, which are potently activated by saturated fatty acids leading to the release of TNF- α [50]. This significantly larger flux of fatty acids likely results in a greater sensitivity to fatty acid-induced inflammation compared with females, providing a plausible explanation for this association. Interestingly, despite the lack of association between changes in weight and airway neutrophils in males, both sexes had a similar improvement to their asthma control and asthma-related quality of life after weight loss. This suggests that clinical asthma improvement operates via a different mechanism in males. While

reduction of adipose tissue may be important in females, it is plausible that the dietary fat restriction that often accompanies weight loss is more important in males.

Of interest was the decrease in sputum eosinophils after exercise. Mendes et al [51] recently found three months of aerobic training significantly reduced sputum eosinophils and exhaled nitric oxide levels in adults with asthma. Additionally, OVA-sensitised mice exercised on a treadmill at a moderate intensity for 45-minutes have a significant reduction in eosinophils in bronchoalveolar lavage [52]. The effect of exercise on airway inflammation appears to occur independent of weight loss, as we observed a significant reduction to airway eosinophils despite no significant weight change after the exercise intervention. The mechanism requires further investigation, however murine models suggest moderate-intensity exercise increases the expression of the anti-inflammatory cytokine IL-10 and reduces IL-5 and IL-4 [52, 53]. While these models demonstrate that exercise of a low-moderate intensity reduces airway eosinophilia, vigorous activity appears to enhance Th2 responses [54]. Our study is the first to demonstrate that moderate-intensity exercise is associated with reduced eosinophilic airway inflammation in humans. It is plausible that physical inactivity may have a role in the aetiology of the obese-asthma phenotype.

This group of asthmatics participated in a greater amount of physical activity at baseline than previous cross-sectional research has suggested. For example, Ford et al [20] found those with asthma partake in less physical activity and are more sedentary than those without asthma, while Westermann et al [55] found that obese asthmatics are less likely to participate in vigorous- and moderate-intensity exercise compared with asthmatics of a healthy weight. In the study by Westermann et al [55] only 37%

of overweight and 19% of obese asthmatics reported participating in vigorous exercise. However, in our study 61% of subjects reported participating in vigorous activity at baseline. Each of these studies utilised questionnaires to calculate physical activity levels; however, the questionnaire used varied across studies, which may account for some of the differences observed. Additionally, it is plausible that the nature of the intervention may have been more appealing to those with a higher baseline level of physical activity, which may explain why the increase in physical activity after the combined intervention did not reach statistical significance.

A limitation of this study was the relatively small number of participants enrolled and as such it may have been underpowered to detect changes in some outcome measures. In order to address this, a per protocol analysis was performed rather than intention to treat analysis, which may also be a limitation. Despite this, some novel findings were observed, thus providing direction for future research. Another limitation is that a non-intervention control group was not recruited. Each of the interventions has been tested previously against placebo, and in this study we sought to compare the comparative efficacy of known interventions. A previous randomised controlled weight loss trial in asthmatic adults demonstrated lung function and asthma symptoms remained stable in control subjects, while these measures were significantly improved after weight loss. This suggests that the improvements we observed are due to the intervention rather than a chance effect resulting from the variability of asthma outcomes. In addition, we saw differential responses in these outcome measures, indicating that the observed changes are more likely to be specific to the interventions rather than chance effects. In addition, while DXA is an accurate and reliable measure of body composition, it does not distinguish visceral from subcutaneous adipose tissue

and therefore the possible independent effects of these adipose depots could not be determined. Lastly, adjustments were not made for multiple comparisons and it is plausible that some of the observed associations may have arisen by chance. However, the prime motive of this study was to form hypotheses for later confirmation.

In conclusion, this study has demonstrated that both caloric restriction and increased exercise improves clinical asthma outcomes in overweight and obese asthmatics. The aetiology of the obese-asthma phenotype is multifactorial, as a reduction in adipose tissue, dietary fat restriction and increased moderate-intensity exercise exerted independent effects. Weight loss and dietary fat restriction appears to reduce activation of innate immune pathways, while increased moderate-intensity exercise appears to down-regulate allergic pathways. Our findings suggest a weight loss goal of 5-10% should be recommended for the clinical management of overweight and obese adults with asthma, while moderate-intensity exercise may be a useful adjunct therapy.

ACKNOWLEDGEMENTS

The authors thank Allyson Upward, Joanne Smart, Megan Jensen, Amber Smith and the HMRI Respiratory Research laboratory staff for their assistance with data acquisition, and Patrick Mcelduff for statistical advice. This research was supported by an NHMRC Centre for Clinical Research Excellence postgraduate scholarship and a Hunter Medical Research Institute Postgraduate student support package sponsored by the Greaves family.

COMPETING INTERESTS

PG has participated in the development of educational material and as a speaker in educational symposia sponsored by GlaxoSmithKline, Pharmaxis, Novartis, AstraZeneca, and BoehringerIngelheim.

AUTHORS CONTRIBUTIONS

HS participated in the design of the study, conducted participant visits, analysed and interpreted the data and drafted the manuscript. PG participated in the design of the study, assisted in interpretation of the data and helped to draft the manuscript. MG participated in the design of the study and drafting the manuscript. JP assisted with acquisition and interpretation of the data and helped to draft the manuscript. PM participated in the design of the study and helped to draft the manuscript. RC participated in the design of the study, interpretation of the data and helped to draft the manuscript. LW participated in the design and coordination of the study, interpretation of the data and helped to draft the manuscript. All authors have read and approved the final manuscript.

REFERENCES

1. Beuther DA, Sutherland ER. Overweight, Obesity, and Incident Asthma: A Meta-analysis of Prospective Epidemiologic Studies. *Am J Respir Crit Care Med*. 2007;175:661-6.
2. Dixon AE, Shade DM, Cohen RI, Skloot GS, Holbrook JT, Smith LJ, et al. Effect of Obesity on Clinical Presentation and Response to Treatment in Asthma. *J Asthma*. 2006;43:553-8.
3. Vortmann M, Eisner MD. BMI and Health Status Among Adults With Asthma. *Obesity*. 2008;16:146-52.
4. Boulet L-P, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. *Respir Med*. 2007;101:2240-7.
5. Fitzpatrick S, Joks R, Silverberg JI. Obesity is associated with increased asthma severity and exacerbations, and increased serum immunoglobulin E in inner-city adults. *Clin Exp Allergy*. 2012;42:747-59.
6. Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. *J Appl Physiol*. 2010;108:206-11.
7. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DYM. Body Mass and Glucocorticoid Response in Asthma. *Am J Respir Crit Care Med*. 2008;178:682-7.
8. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. *Eur Respir J*. 2006;27:495-503.
9. Aaron SD, Fergusson D, Dent R, Chen Y, Vandemheen KL, Dales RE. Effect of Weight Reduction on Respiratory Function and Airway Reactivity in Obese Women. *Chest*. 2004;125:2046-52.

10. Dixon JB, Chapman L, O'Brien P. Marked Improvement in Asthma after Lap-Band® Surgery for Morbid Obesity. *Obes Surg.* 1999;9:385-9.
11. Eneli IU, Skybo T, Camargo Jr CA. Weight loss and asthma: a systematic review. *Thorax.* 2008;63:671-6.
12. Stenius-Aarniala B, Poussa T, Kvarnström J, Grönlund E-L, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. *BMJ.* 2000;320:827-32.
13. Ahroni JH, Montgomery KF, Watkins BM. Laparoscopic Adjustable Gastric Banding: Weight Loss, Co-morbidities, Medication Usage and Quality of Life at One Year. *Obes Surg.* 2005;15:641-7.
14. Macgregor AMC, Greenberg RA. Effect of Surgically Induced Weight Loss on Asthma in the Morbidly Obese. *Obes Surg.* 1993;3:15-21.
15. Nelson WK, Fatima J, Houghton SG, Thompson GB, Kendrick ML, Mai JL, et al. The malabsorptive very, very long limb Roux-en-Y gastric bypass for super obesity: Results in 257 patients. *Surgery.* 2006;140:517-23.
16. Simard B, Turcotte H, Marceau P, Biron S, Hould FS, Lebel S, et al. Asthma and Sleep Apnea in Patients with Morbid Obesity: Outcome after Bariatric Surgery. *Obes Surg.* 2004;14:1381-8.
17. Sultan S, Parikh M, Youn H, Kurian M, Fielding G, Ren C. Early U.S. outcomes after laparoscopic adjustable gastric banding in patients with a body mass index less than 35 kg/m². *Surg Endosc.* 2009;23:1569-73.
18. Dixon AE, Pratley RE, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Griffes LA, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. *J Allergy Clin Immunol.* 2011;128:508-15.

19. Garcia-Aymerich J, Varraso R, Antó JM, Camargo Jr CA. Prospective Study of Physical Activity and Risk of Asthma Exacerbations in Older Women. *Am J Respir Crit Care Med*. 2009;179:999-1003.
20. Ford ES, Heath GW, Mannino DM, Redd SC. Leisure-Time Physical Activity Patterns Among US Adults With Asthma. *Chest*. 2003;124:432-7.
21. Armstrong T, Bauman A, Davies J. Physical activity patterns of Australian adults. Results of the 1999 National Physical Activity Survey. Canberra: Australian Institute of Health and Welfare; 2000.
22. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster Analysis and Clinical Asthma Phenotypes. *Am J Respir Crit Care Med*. 2008;178:218-24.
23. Scott HA, Gibson PG, Garg ML, Wood LG. Airway Inflammation is Augmented by Obesity and Fatty Acids in Asthma. *Eur Respir J*. 2011;38:594-602.
24. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma. *Am J Respir Crit Care Med*. 2000;161:1185-90.
25. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. *J Immunol*. 1995;154:4719-25.
26. Telenga ED, Tideman SW, Kerstjens HAM, ten Hacken NHT, Timens W, Postma DS, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. *Allergy*. 2012;In Press. DOI: 10.1111/j.1398-9995.2012.02855.x.
27. Ilavská S, Horváthová M, Szabová M, Nemessányi T, Jahnová E, Tulinská J, et al. Association between the human immune response and body mass index. *Human Immunology*. 2012;73:480-5.

28. National Health and Medical Research Council. Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults. Canberra: NHMRC; 2003.
29. Scott HA, Gibson PG, Garg ML, Pretto JJ, Morgan PJ, Callister R, et al. Relationship between body composition, inflammation and lung function in overweight and obese asthma. *Respir Res.* 2012;13:10.
30. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International Physical Activity Questionnaire: 12-Country Reliability and Validity. *Med Sci Sports Exerc.* 2003;35:1381-95.
31. Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)—Short and Long Forms. 2005 [31/05/2011]; Available from: <http://www.ipaq.ki.se/scoring.pdf>.
32. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. *Eur Respir J.* 1999;14:902-7.
33. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. *Am Rev Respir Dis.* 1993;147:832-8.
34. Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. *Respir Med.* 2005;99:553-8.
35. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a Minimal Important Change in a Disease-Specific Quality of Life Questionnaire. *J Clin Epidemiol.* 1994;47:81-7.
36. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J.* 2005;26:319-38.
37. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. *Eur Respir J.* 2005;26:511-22.

38. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AW, et al. Epidemiological Association of Airway Inflammation with Asthma Symptoms and Airway Hyperresponsiveness in Childhood. *Am J Respir Crit Care Med*. 1998;158:36-41.
39. Juniper EF, Bousquet J, Abetz L, Bateman ED, The GOAL Committee. Identifying 'well-controlled' asthma using the Asthma Control Questionnaire. *Respir Med*. 2006;100:616-21.
40. Anderson JW, Vichitbandra S, Qian W, Kryscio R. Long-Term Weight Maintenance after an Intensive Weight-Loss Program. *J Am Coll Nutr*. 1999;18:620-7.
41. Fontana L, Villareal DT, Weiss EP, Racette SB, Steger-May K, Klein S, et al. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. *Am J Physiol Endocrinol Metab*. 2007;293:E197-E202.
42. Katznel LI, Bleecker ER, Colman EG, Rogus EM, Sorkin JD, Goldberg AP. Effects of Weight Loss vs Aerobic Exercise Training on Risk Factors for Coronary Disease in Healthy, Obese, Middle-aged and Older Men: A Randomized Controlled Trial. *JAMA*. 1995;274:1915-21.
43. Nijhuis J, Rensen SS, Slaats Y, van Dielen FM, Buurman WA, Greve JW. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. *Obesity*. 2009;17:2014-8.
44. Shah TJ, Leik CE, Walsh SW. Neutrophil infiltration and systemic vascular inflammation in obese women. *Reprod Sci*. 2009;17:116-24.
45. Van Harmelen V, Reynisdottir S, Eriksson P, Thörne A, Hoffstedt J, Lönnqvist F, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. *Diabetes*. 1998;47:913-7.

46. Zarkesh-Esfahani H, Pockley AG, Wu Z, Hellewell PG, Weetman AP, Ross RJ. Leptin indirectly activates human neutrophils *via* induction of TNF- α . J Immunol. 2004;172:1809-14.
47. Bruno A, Conus S, Schmid I, Simon H-U. Apoptotic Pathways Are Inhibited by Leptin Receptor Activation in Neutrophils. J Immunol. 2005;174:8090-6.
48. Power ML, Schulkin J. Sex differences in fat storage, fat metabolism, and the health risks from obesity: possible evolutionary origins. Br J Nutr. 2008;99:931-40.
49. Shi H, Clegg DJ. Sex differences in the regulation of body weight. Physiol Behav. 2009;97:199-204.
50. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008;582:97-105.
51. Mendes FAR, Almeida FA, Cukier A, Stelmach R, Jacob-Filho W, Martins MA, et al. Effects of Aerobic Training on Airway Inflammation in Asthmatic Patients. Med Sci Sports Exerc. 2011;43:197-203.
52. Hewitt M, Creel A, Estell K, Davis IC, Schwiebert LM. Acute Exercise Decreases Airway Inflammation, but Not Responsiveness, in an Allergic Asthma Model. Am J Respir Cell Mol Biol. 2009;40:83-9.
53. Vieira RP, Claudino RC, Duarte ACLS, Santos AnBG, Perini A, Neto HCCF, et al. Aerobic Exercise Decreases Chronic Allergic Lung Inflammation and Airway Remodeling in Mice. Am J Respir Crit Care Med. 2007;176:871-7.
54. Pedersen BK, Toft AD. Effects of exercise on lymphocytes and cytokines. Br J Sports Med. 2000;34:246-51.
55. Westermann H, Choi TN, Briggs WM, Charlson ME, Mancuso CA. Obesity and exercise habits of asthmatic patients. Ann Allergy Asthma Immunol. 2008;101:488-94.

Figure 1. Flowchart of study participants.

Figure 2a) Mean $\pm$ SD percent weight loss, **b).** median (IQR) waist circumference change, **c).** median (IQR) fat mass change, and **d).** median (IQR) muscle mass change, by intervention. Within group changes are shown below each figure; significant between group differences are shown above each figure.

Figure 3a) Change to asthma-related quality of life (AQLQ) – pre- versus post-intervention. Data are presented as median (interquartile range).

Figure 3b) Clinically significant improvement to asthma-related quality of life (AQLQ) – pre- versus post-intervention, by intervention. A clinically significant improvement to AQLQ score was defined as an increase in the overall score of ≥ 0.5 [35].

Figure 3c) Change to asthma control (ACQ) – pre- versus post-intervention.

Figure 3d) Clinically significant improvement to asthma control (ACQ) – pre- versus post-intervention, by intervention. A clinically significant improvement to ACQ score was defined as a decrease in the total score of ≥ 0.5 [34]. Data are presented as median (interquartile range).

Figure 3e) Clinically significant improvement to asthma-related quality of life (AQLQ) – pre- versus post-intervention, by weight loss.

Figure 3f) Clinically significant improvement to asthma control (ACQ) – pre- versus post-intervention, by weight loss.

Table 1. Subject baseline characteristics, by intervention.

	Dietary	Exercise	Combined
N	15	10	13
Sex (%Female)	53.3	50.0	53.9
Age (years)	44.7±14.7	42.2±11.5	33.9±11.5
BMI (kg/m²)	34.7±4.0	32.8±2.5	32.7±3.4
Waist Circumference (cm)	112.9±11.4	108.6±8.0	109.2±10.7
Total Body Fat (%)	44.1 (40.7, 52.6)	42.6 (33.6, 48.7)	47.9 (36.7, 51.8)
FEV₁ %predicted	80.8±18.5	87.7±16.0	78.4±16.8
FVC %predicted	92.1±14.7	96.8±12.3	94.0±13.5
FEV₁/FVC (%)	73.2 (58.7, 77.0)	73.2 (66.9, 80.4)	68.2 (64.0, 78.4)
TLC %predicted	100.5 (87.5, 106.6)	98.7 (87.9, 102.5)	95.6 (93.1, 96.7)
FRC %predicted	94.5 (73.8, 115.0)	85.6 (71.7, 116.0)	90.6 (83.2, 105.8)
ERV %predicted	109.6±27.3	113.8±45.0	114.2±27.3
RV %predicted	85.6 (57.3, 105.1)	62.7 (47.5, 94.1)	61.7 (49.0, 80.7)
Atopy (%)	86.7	77.8	92.3
ICS Dose (µg/day) †	1000 (0, 1000)	1000 (500, 1000)	1000 (0, 1000)
Ever Smokers (%)	33.3	30.0	30.8
Pack Years of Ever Smokers	8 (3, 15)	2 (1, 27)	5 (1, 8)
Age at Asthma Diagnosis (years)	8 (2, 40)	5 (2, 32)	9 (6, 16)
ACQ Score	1.24±0.57	1.00±0.71	1.36±0.63
AQLQ Score	5.8 (5.4, 6.1)	6.1 (5.0, 6.3)	5.8 (4.8, 6.1)
GINA Classification (%) (Intermittent/Mild/Moderate/Severe)	27/27/27/20	30/30/40/0	8/23/54/15
Systemic Inflammatory Markers			
Leptin (µg/L)	13.8 (7.1, 22.8)	11.8 (6.2, 20.0)	19.7 (5.6, 33.4)
Adiponectin (mg/L)	5.9 (4.7, 9.2)	4.3 (2.9, 7.1)	7.9 (2.9, 28.5)
CRP (mg/L)	3.6 (1.2, 8.0)	2.3 (1.0, 7.1)	3.6 (1.9, 5.8)
IL-6 (pg/mL)	1.6 (0.8, 2.1)	1.0 (0.7, 1.3)	1.4 (1.1, 2.0)
Airway Inflammatory Markers			
Total Cell Count (×10 ⁶ /mL)	4.1 (2.4, 5.0)	2.3 (1.6, 6.2)	1.5 (1.2, 5.9)
Neutrophils (%)	34.7±24.0	37.6±19.5	27.1±23.7
Eosinophils (%)	2.3 (0.3, 6.8)	2.8 (1.3, 4.3)	4.3 (2.0, 15.3)
Macrophages (%)	57.9±22.1	55.1±18.1	56.8±17.5
Lymphocytes (%)	1.3 (0.5, 1.5)	0.9 (0.3, 2.0)	0.8 (0.6, 2.0)
Comorbidities (%)			
Gastro-oesophageal Reflux	0	20.0	15.4
Hypertension	20.0	30.0	46.2
Hypercholesterolaemia	13.3	10.0	23.1
Depression/Anxiety	26.7	20.0	15.4

Data presented as mean±SD, median (IQR) or % the percentage of subjects with the specified variable. BMI – body mass index; FEV₁ – forced expiratory volume in one second; FVC – forced vital capacity; TLC – total lung capacity; FRC – functional residual capacity; ERV – expiratory reserve volume; RV – residual volume; ICS – inhaled corticosteroid; ACQ – asthma control questionnaire; AQLQ – asthma-related quality of life questionnaire; GINA – Global Initiative for Asthma; Mild - Mild Persistent; Moderate – Moderate Persistent; Severe – Severe Persistent; CRP – C-reactive protein; IL-6 – Interleukin-6. † Beclomethasone equivalents. Comorbidities were determined by self-report, medication usage, and measurement of blood pressure and total fasting cholesterol.

Table 2. Change in body composition, dietary macronutrient intake and physical activity by treatment group.

Characteristic	Dietary (n=15)		Exercise (n=10)		Combined (n=13)		Group Effect (P-value)
	Baseline	Change	Baseline	Change	Baseline	Change	
Weight (kg)	101.0±17.6	-8.4±4.4 †***	97.6±9.1	-1.8±2.7	96.7±9.3	-8.2±5.1 †***	0.001
Waist Circumference (cm)	112.9±11.4	-8.5 (-11.7, -6.3) †***	109.4 (106.0, 114.2)	-3.4 (-5.8, -2.1) **	107.3 (103.2, 116.6)	-10.4 (-11.6, -7.5) †**	0.001
Fat - Total (kg)	42.7±12.6	-6.0±4.1 †***	39.1±6.4	-1.3±2.2	40.3±9.3	-6.5±4.0 †***	0.002
Fat - Android (kg)	4.5±1.4	-0.7 (-1.2, -0.6) †***	3.8 (3.5, 4.4)	-0.4 (-0.6, -0.2) **	3.9 (3.1, 4.8)	-0.5 (-1.0, -0.4) **	0.045
Fat - Gynoid (kg)	7.2 (5.1, 9.2)	-1.1 (-1.4, -0.9) †**	7.2 (5.8, 8.9)	-0.2 (-0.3, 0)	7.0 (5.9, 8.4)	-1.0 (-1.6, -0.8) †**	0.002
Fat - Thoracic (kg)	10.9 (9.4, 14.1)	-2.6 (-4.0, -0.4) **	10.5 (9.2, 11.2)	-1.0 (-1.6, -0.8)	10.6 (9.0, 12.7)	-2.7 (-3.2, -0.7)	0.147
Fat - Arms (kg)	3.7 (2.5, 4.5)	-0.6 (-1.0, -0.2) *	3.4 (2.7, 4.3)	-0.1 (-0.3, 0)	4.1 (3.3, 4.4)	-0.8 (-1.1, -0.4) †**	0.098
Fat - Legs (kg)	14.9 (10.6, 17.9)	-1.9 (-2.8, -1.2) †**	13.7 (10.3, 19.2)	-0.5 (-0.8, 0.4)	12.4 (10.9, 19.1)	-1.5 (-2.9, -1.4) †**	0.017
Lean - Total (kg)	47.5 (45.6, 63.6)	-1.3 (-2.4, -0.5) **	56.3 (44.1, 65.5)	-1.2 (-1.9, 1.7)	55.2 (44.0, 60.8)	-1.2 (-2.3, 0.7)	0.382
Lean - Android (kg)	3.8 (3.6, 4.6)	-0.1 (-0.4, -0.1) *	3.9 (3.1, 4.6)	-0.3 (-0.3, 0.1)	3.8 (3.1, 4.2)	0.1 (-0.3, 0.1)	0.724
Lean - Gynoid (kg)	7.1 (6.5, 9.7)	-0.2 (-0.5, -0.1) *	7.9 (6.6, 9.3)	-0.1 (-0.2, 0.2)	7.8 (6.5, 9.4)	-0.5 (-0.6, 0.1) †*	0.111
Lean - Thoracic (kg)	15.0 (12.0, 20.9)	-1.1 (-2.3, 0.2) **	17.3 (12.4, 18.9)	-0.8 (-1.2, -0.1)	15.9 (12.5, 17.4)	-0.5 (-1.9, 0.9)	0.437
Lean - Arms (kg)	4.9 (4.6, 8.6)	-0.2 (-0.9, 0.3)	6.1 (4.3, 7.4)	0.1 (-0.2, 0.5)	5.8 (4.6, 8.2)	-0.3 (-0.4, 0) *	0.172
Lean - Legs (kg)	16.7 (15.2, 22.6)	-0.4 (-1.0, 0.2)	19.1 (15.6, 24.3)	0.3 (-0.6, 0.6)	18.7 (15.7, 21.5)	-0.5 (-0.9, 0.2)	0.467
Energy (kJ)	8961 (7137, 11616)	-4261 (-5896, -2632) †**	9825 (8749, 11874)	-232 (-3254, 464)	11449 (10000, 12432)	-5584 (-7386, -4624) †**	<0.001
Fat (g)	84 (77, 113)	-46 (-83, -38) †**	80 (68, 87)	0 (-40, 9)	121 (110, 136)	-90 (-94, -63) †**	<0.001
SFA (g)	35 (28, 50)	-24 (-35, -13) †**	36 (30, 39)	-7 (-22, 7)	46 (43, 47)	-30 (-37, -25) †**	<0.001
MUFA (g)	34 (26, 45)	-19 (-30, -13) †**	30 (26, 35)	2 (-13, 6)	48 (45, 59)	-37 (-38, -25) †**	0.001
PUFA (g)	12 (10, 16)	-5 (-9, -2) †**	11 (9, 11)	1 (-4, 1)	17 (15, 22)	-11 (-13, -8) †**	0.020
Carbohydrate (g)	213 (191, 293)	-120 (-162, -85) †**	302 (196, 365)	-26 (-104, -15)	224 (200, 312)	-95 (-142, -64) †**	<0.001
Sugars (g)	109 (83, 131)	-46 (-70, -26) †**	90 (89, 146)	13 (0, 18)	102 (76, 164)	4 (-90, 10) †	0.001
Protein (g)	100 (84, 132)	-1 (-34, 14)	108 (103, 144)	-9 (-10, -8)	128 (108, 156)	-36 (-70, -21) *	0.407
Total Physical Activity	2347 (1188, 4176)	495 (-825, 3473)	3079 (2382, 6120)	2651 (389, 7428) *	3333 (2217, 8052)	2267 (691, 4812)	0.720
Vigorous Activity	320 (0, 1574)	480 (0, 3120)	80 (0, 360)	1200 (720, 3840) **	960 (480, 2160)	480 (160, 1440)	0.494
Moderate Activity	240 (0, 1680)	0 (-120, 1440)	180 (0, 3600)	1200 (720, 3840)	960 (360, 1440)	360 (-60, 1320)	0.696
Walking	495 (297, 3465)	0 (-693, 347)	2608 (792, 3960)	74 (-215, 4356)	1386 (462, 4752)	231 (-132, 1089)	0.124
Sitting Time (mins/day)	300 (180, 420)	0 (-120, 60)	330 (180, 540)	-120 (-180, 0) *	240 (210, 300)	-30 (-120, 30)	0.516
Step Count (steps/day)	7239±2969	1000±3063	8335±3607	1867±2190	10186±3328	1958±3117	0.147

Data presented as median (IQR) or mean±standard deviation. SFA – saturated fatty acids; MUFA – monounsaturated fatty acids; PUFA – polyunsaturated fatty acids. Physical activity level was calculated as Metabolic Equivalent Task (MET) minutes/week. METS are multiples of the resting metabolic rate. MET-minutes were calculated by multiplying the MET score of the level of activity by the minutes it was performed [31]. † significant difference in change from baseline versus the exercise group. There was no significance in change between the dietary and combined interventions. * $p \leq 0.05$ vs pre-intervention; ** $p \leq 0.01$ vs pre-intervention; *** $p \leq 0.001$ vs pre-intervention.

Table 3. Change in clinical asthma outcomes, and airway and systemic inflammatory markers, by treatment group.

Characteristic	Dietary (n=15)		Exercise (n=10)		Combined (n=13)		Group Effect (P-value)
	Baseline	Change	Baseline	Change	Baseline	Change	
FEV ₁ (L)	2.80±0.98	0.08±0.31	3.23±1.00	0.07±0.16	2.96±0.81	0.07±0.30	0.999
FVC (L)	4.00±1.19	0.12±0.10	4.41±1.06	0.13±0.32	4.34±1.14	0.18±0.31	0.923
FEV ₁ /FVC (%)	73.2 (58.7, 77.0)	-0.5 (-2.3, 3.0)	73.2 (66.9, 80.4)	0.2 (-2.2, 1.0)	68.2 (64.0, 78.4)	-0.7 (-3.6, 0.7)	0.735
TLC (L)	5.31 (4.68, 7.44)	-0.03 (-0.33, 0.14)	5.79 (5.36, 6.71)	0.13 (-0.02, 0.28) †	5.17 (4.89, 6.97)	0.06 (-0.06, 0.33) †	0.037
FRC (L)	2.69 (2.04, 3.55)	0.07 (-0.23, 0.28)	2.63 (2.46, 3.10)	0.09 (0.04, 0.26)	2.86 (2.32, 3.34)	0.11 (-0.15, 0.420)	0.922
ERV (L)	1.33±0.53	0.28±0.43 *	1.44±0.58	0.12±0.32	1.59±0.53	0.12±0.39	0.456
RV (L)	1.53 (0.90, 2.01)	-0.12 (-0.57, 0.01)	1.06 (0.71, 2.06)	0.07 (-0.13, 0.12)	1.12 (0.71, 1.69)	-0.04 (-0.30, 0.39)	0.560
Dose Response Slope ‡	1.2 (0.5, 3.2)	0.1 (-0.7, 0.7)	1.0 (0.5, 1.7)	-0.6 (-0.9, 0.2)	2.3 (1.7, 3.4)	-0.7 (-1.6, 1.0)	0.295
ACQ Score	1.2±0.6	-0.6±0.5 ***	1.2±0.6	-0.3±0.5	1.4±0.6	-0.5±0.7 *	0.343
AQLQ Score	5.8 (5.4, 6.1)	0.9 (0.4, 1.3) **	5.8 (5.4, 6.1)	0.49 (0.03, 0.78) *	5.8 (4.8, 6.1)	0.5 (0.1, 1.0) **	0.212
Airway Markers							
Total Cell Count (×10 ⁶ /mL)	4.1 (2.4, 5.0)	0.9 (-1.1, 1.6)	2.3 (1.6, 6.2)	2.2 (-0.2, 4.2)	1.5 (1.2, 5.9)	1.8 (0.4, 0)	0.986
Neutrophils (%)	29.4 (22.3, 40.8)	4.5 (-5.8, 18.0)	32.4 (28.8, 58.3)	2.0 (-18.3, 9.0)	23.8 (3.0, 39.0)	2.8 (-3.8, 18.0)	0.754
Eosinophils (%)	2.3 (0.3, 6.8)	0.3 (-1.5, 1.8)	2.8 (1.3, 4.3)	-1.3 (-2.0, -1.0)*	4.3 (2.0, 15.3)	-0.5 (-15.3, 8.9)	0.763
Macrophages (%)	57.9±22.1	-3.7±17.7	55.1±18.1	3.9±23.0	56.8±17.5	8.0±29.1	0.581
Lymphocytes (%)	1.3 (0.5, 1.5)	0.4 (-0.9, 1.1)	0.9 (0.3, 2.0)	-0.5 (-1.3, 0)	0.8 (0.6, 2.0)	0.5 (-1.8, 1.5)	0.074
Systemic Markers							
Leptin (ug/L)	13.8 (7.1, 22.8)	-5.3 (-8.6, -3.5) **	11.8 (6.2, 20.0)	-1.2 (-4.8, 1.7)	19.7 (5.6, 33.4)	-6.2 (-9.7, -2.7) **	0.425
Adiponectin (mg/L)	5.9 (4.7, 9.2)	0.02 (-0.83, 1.13)	4.3 (2.9, 7.1)	-0.27 (-0.71, 0.03)	7.9 (2.9, 28.5)	-0.44 (-0.54, 0.46)	0.716
CRP (mg/L)	3.6 (1.2, 8.0)	-0.6 (-2.1, 0.5)	2.3 (1.0, 7.1)	-0.7 (-1.1, 0)	3.6 (1.9, 5.8)	-0.4 (-0.8, 0)	0.280
IL-6 (pg/mL)	1.6 (0.8, 2.1)	-0.02 (-0.59, 0.32)	1.0 (0.7, 1.3)	0.23 (-0.09, 0.31)	1.4 (1.1, 2.0)	-0.18 (-0.56, 0.01) *	0.300

Data presented as median (IQR) or mean±standard deviation. FEV₁ – forced expiratory volume in one second; FVC – forced vital capacity; TLC – total lung capacity; FRC – functional residual capacity; ERV – expiratory reserve volume; RV – residual volume; ACQ – asthma control questionnaire; AQLQ – asthma-related quality of life questionnaire; CRP – C-reactive protein; IL-6 – Interleukin-6. † significant difference in change from baseline versus the dietary group. There was no significance in change between the exercise and combined interventions. * $p \leq 0.05$ vs pre-intervention; ** $p \leq 0.01$ vs pre-intervention; *** $p \leq 0.001$ vs pre-intervention. ‡ Provocation fall (%) ÷ provocation dose of 4.5% hypertonic saline (mL), after hypertonic saline challenge.

Table 4. Change in clinical asthma characteristics (pre- versus post-intervention), by weight loss.

Variable Change	<5% Weight Loss	5-10% Weight Loss	>10% Weight Loss	P-value
N	16	12	10	
FEV ₁ (L)	-0.02±0.18	0.2±0.3	0.1±0.3	0.124
FVC (L)	0.02±0.20	0.25±0.36 †	0.20±0.32	0.108
FEV ₁ /FVC (%)	-1.3 (-2.3, 1.0)	0.1 (-2.0, 3.8)	-0.7 (-3.3, 0.7)	0.691
TLC (L)	0 (-0.1, 0.2)	0 (-0.2, 0.3)	0 (-0.2, 0.4)	0.993
FRC (L)	0.1 (0, 0.3)	0 (-0.3, 0.1)	0.4 (0.2, 0.5)†§	0.018
ERV (L)	0.11±0.31	0.02±0.32	0.49±0.42 †‡§	0.008
RV (L)	0 (-0.1, 0.1)	-0.1 (-0.4, 0.2)	-0.1 (-0.8, 0.2)	0.792
ACQ	-0.30±0.46 †	-0.64±0.49 †	-0.54±0.77	0.277
AQLQ	0.43 (0.03, 0.60) †	0.83 (0.60, 1.36) †	0.80 (0.40, 1.34) †	0.063

Data presented as mean±SD or median (IQR). FEV₁ – forced expiratory volume in one second; FVC – forced vital capacity; TLC – total lung capacity; FRC – functional residual capacity; ERV – expiratory reserve volume; RV – residual volume; ACQ – asthma control questionnaire; AQLQ – asthma-related quality of life questionnaire. † significant difference between pre-intervention vs post-intervention; ‡ significantly different change vs <5% weight loss; § significantly different change vs 5-10% weight loss.

Table 5. The relationship between the change in airway inflammation and change in physical activity in all subjects pre- versus post-intervention (n=29).

	Neutrophils (%)	Eosinophils (%)
Total Physical Activity	0.286	-0.398 *
Vigorous Physical Activity	0.091	0.008
Moderate Physical Activity	0.216	-0.444 *
Walking	0.277	-0.353
Sitting Time (mins/day)	-0.394 *	0.133
Step Count (Steps/Day)	0.040	-0.254

Partial correlations adjusted for age and inhaled corticosteroid use. * $p \leq 0.05$.

Table 6. The relationship between the change in airway inflammation and changes to body composition, dietary fat intake and systemic inflammation pre- *versus* post-intervention in males and females.

	Males (n=14)		Females (n=15)	
	Neutrophils (%)	Eosinophils (%)	Neutrophils (%)	Eosinophils (%)
Weight (%)	-0.259	0.049	0.640*	0.049
Waist	-0.166	-0.050	0.183	0.390
Circumference (cm)				
Fat Mass (%)				
Total	-0.003	-0.320	0.579*	0.136
Android	-0.380	-0.106	0.546	-0.008
Gynoid	-0.070	-0.196	0.561*	0.029
Thoracic	-0.107	-0.425	0.411	-0.023
Arms	-0.069	-0.337	0.648*	-0.285
Legs	-0.016	-0.197	0.571*	0.094
Lean Mass (%)				
Total	-0.133	0.490	0.261	-0.357
Android	-0.580*	0.688*	0.264	-0.347
Gynoid	-0.234	0.455	-0.175	-0.227
Thoracic	-0.175	0.626*	0.273	-0.569*
Arms	-0.103	-0.049	0.392	-0.493
Legs	0.047	-0.193	0.064	0.024
Energy (kJ)	-0.526	0.426	-0.437	0.346
Fat (g)	0.417	-0.681	-0.001	0.316
SFA (g)	0.472	-0.561	-0.246	0.237
MUFA (g)	0.547	-0.795*	0.119	0.233
PUFA (g)	-0.357	-0.042	0.149	0.404
Linoleic Acid	-0.309	-0.053	0.165	0.405
Linolenic Acid	-0.200	-0.307	0.620	-0.106
Leptin (µg/L)	-0.368	0.288	0.196	0.144
Adiponectin (mg/L)	0.205	-0.062	0.083	-0.079
CRP(mg/L)	-0.249	0.534	0.109	0.030
IL-6 (pg/mL)	-0.176	-0.005	-0.168	0.104

Values reported are partial correlations adjusted for age and inhaled corticosteroid use. Dietary fat intake also adjusted for energy intake (kJ). * $p \leq 0.05$.